Jade Biosciences (JBIO) Net Cash Flow (2020 - 2026)

Jade Biosciences has reported Net Cash Flow for 7 years, with the latest figure at -$33.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 404.99% year-over-year to -$33.4 million; the trailing twelve-month figure through Mar 2026 stood at -$7.7 million (down 104.69% YoY), and the FY2025 full-year result was $19.1 million, up 85.9% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$33.4 million, down from $38.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $158.2 million in Q2 2025, with the low at -$170.8 million in Q3 2025.
• Historically, Net Cash Flow has averaged $6.9 million across 5 years, with a median of -$2.9 million in 2022.
• The largest YoY upside for Net Cash Flow was 5133.72% in 2023 against a maximum downside of 39395.45% in 2023.
• Jade Biosciences' Net Cash Flow stood at -$22000.0 in 2022, then plunged by 39395.45% to -$8.7 million in 2023, then jumped by 1049.65% to $82.5 million in 2024, then sank by 53.57% to $38.3 million in 2025, then sank by 187.09% to -$33.4 million in 2026.
• The last three Net Cash Flow figures came in at -$33.4 million (Q1 2026), $38.3 million (Q4 2025), and -$170.8 million (Q3 2025), per Business Quant data.